Clinical development in disease therapies of interest like Cancer, CVS and CNS in the last 2-3 years has made the researchers of Big Pharma work in the direction of the developing newer drugs in these areas. Chronic therapies like the one mentioned above drive the investors to invest with Big Pharma/ Big and small bio Pharma to invest in the clinical development of these drugs. The clinical Trials are conducted various sites specified geographic locations based on the patient availability and the protocol design. Sites which are investigator specific are targeted on priority. Regulatory compliance related adherence of GCP guidelines are conducted before and during the course of the trial. The Site specific standard operating procedures are reviewed on an ongoing basis by the relevant regulatory supremacy of the concerned geographic region.
The nature of the clinical results in the Post phase I onwards i.e. Phase II onwards determines the flow of the trial to the next stage. The stage is critical for further progress of the trial form the investor’s perspective especially if the company conducting the trial is a listed company. The Stock rating of the company is likely to be the most affected when the relevant trial results are released to the media and the stock market.
As the boundaries of risk mitigation in clinical development do not “touch” a defined benchmark, clinical trial results would continue to remain the Key point of clinical development.
Veeda Oncology® is dedicated to providing clinical oncology research services internationally for the pharmaceutical and biotech industries. With offices in the US, Europe and India, Veeda Oncology is in the unparalleled position to meet both the regional and global needs of our sponsors. We are one of the few companies whose main focus is oncology. As a result, Veeda Oncology can meet the rigors of local and global requirements of Phase I through Phase IV programs